(Q28300267)

https://api.crossref.org/works/10.1080/10428190400007565

The phosphatidylinositol 3-Kinase AKT pathway in human cancer

20 April 2017

1 reference

https://api.crossref.org/works/10.1080%2F10428190400007565

Core-binding factors in haematopoiesis and leukaemia

20 April 2017

1 reference

https://api.crossref.org/works/10.1080%2F10428190400007565

Amplification of a novel c-Kit activating mutation Asn(822)-Lys in the Kasumi-1 cell line: a t(8;21)-Kit mutant model for acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190400007565

AML1-ETO expression is directly involved in the development of acute myeloid leukemia in the presence of additional mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190400007565

Expression of a conditional AML1-ETO oncogene bypasses embryonic lethality and establishes a murine model of human t(8;21) acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190400007565

Genetics of myeloid leukemias

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190400007565

The c-KIT mutation causing human mastocytosis is resistant to STI571 and other KIT kinase inhibitors; kinases with enzymatic site mutations show different inhibitor sensitivity profiles than wild-type kinases and those with regulatory-type mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190400007565

The 8;21 translocation in leukemogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190400007565

Embryonic lethality and impairment of haematopoiesis in mice heterozygous for an AML1-ETO fusion gene.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190400007565

AML1-ETO downregulates the granulocytic differentiation factor C/EBPalpha in t(8;21) myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190400007565

Inhibition of the transforming growth factor beta 1 signaling pathway by the AML1/ETO leukemia-associated fusion protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190400007565

Induction of apoptosis in myeloid leukaemic cells by ribozymes targeted against AML1/MTG8

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190400007565

AML1/MTG8 oncogene suppression by small interfering RNAs supports myeloid differentiation of t(8;21)-positive leukemic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190400007565

Haploinsufficiency of CBFA2 causes familial thrombocytopenia with propensity to develop acute myelogenous leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190400007565

Hematopoietic stem cell expansion and distinct myeloid developmental abnormalities in a murine model of the AML1-ETO translocation

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190400007565

In utero origin of t(8;21) AML1-ETO translocations in childhood acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190400007565

An activated receptor tyrosine kinase, TEL/PDGFbetaR, cooperates with AML1/ETO to induce acute myeloid leukemia in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190400007565

21 January 2018

Focus on acute leukemias

1 reference

https://api.crossref.org/works/10.1080%2F10428190400007565

The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the Unite

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190400007565

FLT3 internal tandem duplication in 234 children with acute myeloid leukemia: prognostic significance and relation to cellular drug resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190400007565

Kit signaling through PI 3-kinase and Src kinase pathways: an essential role for Rac1 and JNK activation in mast cell proliferation

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190400007565

Phosphatidylinositol 3 kinase contributes to the transformation of hematopoietic cells by the D816V c-Kit mutant

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190400007565

Signal transducer and activator of transcription 3 activation is required for Asp(816) mutant c-Kit-mediated cytokine-independent survival and proliferation in human leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190400007565

Necessity of tyrosine 719 and phosphatidylinositol 3'-kinase-mediated signal pathway in constitutive activation and oncogenic potential of c-kit receptor tyrosine kinase with the Asp814Val mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190400007565

Early signaling pathways activated by c-Kit in hematopoietic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190400007565

The protein tyrosine kinase inhibitor SU5614 inhibits VEGF-induced endothelial cell sprouting and induces growth arrest and apoptosis by inhibition of c-kit in AML cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190400007565

Autocrine stimulation of VEGFR-2 activates human leukemic cell growth and migration

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190400007565

Vascular endothelial growth factor receptor-1 and receptor-2 initiate a phosphatidylinositide 3-kinase-dependent clonogenic response in acute myeloid leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190400007565

The antiangiogenic protein kinase inhibitors SU5416 and SU6668 inhibit the SCF receptor (c-kit) in a human myeloid leukemia cell line and in acute myeloid leukemia blasts

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190400007565

Sustained complete hematologic remission after administration of the tyrosine kinase inhibitor imatinib mesylate in a patient with refractory, secondary AML.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190400007565

The myeloid master regulator transcription factor PU.1 is inactivated by AML1-ETO in t(8;21) myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190400007565